- Title
- Real-world treatment patterns and outcomes for patients with CLL using the Australian pharmaceutical benefits scheme (PBS) dataset
- Creator
- Tam, Constantine; Zhao, Fei-Li; Azam, Safee; Li, Shu Chuen; Tang, Boxiong
- Relation
- Leukemia and Lymphoma Vol. 65, Issue 11, p. 1576-1585
- Publisher Link
- http://dx.doi.org/10.1080/10428194.2024.2374040
- Publisher
- Taylor & Francis
- Resource Type
- journal article
- Date
- 2024
- Description
- This real-world retrospective cohort study using Australian Pharmaceutical Benefits Scheme (PBS) 10% investigated changes in chronic lymphocytic leukemia (CLL) treatment by line of therapy, time-to-next-treatment, treatment duration, and overall survival (OS). Overall, 803 patients received their first PBS-reimbursed CLL medication between 1 January 2011 to 31 July 2021 (median age: 70 years; 64.6% male), 289 post-1 August 2020. In 2011, most first-line (1 L) prescribing was fludarabine, cyclophosphamide, and rituximab (FCR). By 2021, common 1L were chlorambucil ± CD20 (26.1%), Bruton Tyrosine Kinase inhibitor (BTKi) (26.1%), and CD20 monotherapy (23.9%). In 2011, relapsed/refractory (R/R) CLL treatment was CD20 monotherapy or FCR. By 2021, BTKi (57.7%) and venetoclax ± CD20 (26.1%) were most common. Compared to FCR, 1 L treatment duration (Hazard Ratio) was shorter for CD20 monotherapy (1.7) or chlorambucil ± CD20 (2.5). In R/R CLL, median duration was 24 (ibrutinib) and 19 months (venetoclax). Median OS was 127 months. CLLtreatment pattern shave greatly changed in Australia since the introduction of novel therapies.
- Subject
- chronic lymphocytic leukemia; real-world study; bruton tyrosine kinase inhibitor; Pharmaceutical Benefits Scheme (PBS); SDG 3; Sustainable Development Goal
- Identifier
- http://hdl.handle.net/1959.13/1516215
- Identifier
- uon:56962
- Identifier
- ISSN:1042-8194
- Rights
- © 2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- Language
- eng
- Full Text
- Reviewed
- Hits: 196
- Visitors: 208
- Downloads: 14
| Thumbnail | File | Description | Size | Format | |||
|---|---|---|---|---|---|---|---|
| View Details Download | ATTACHMENT01 | Publisher version (open access) | 2 MB | Adobe Acrobat PDF | View Details Download |